Regen Biopharma Stock Current Liabilities
| RGBP Stock | USD 0.1 0 4.39% |
Regen BioPharma fundamentals help investors to digest information that contributes to Regen BioPharma's financial success or failures. It also enables traders to predict the movement of Regen Pink Sheet. The fundamental analysis module provides a way to measure Regen BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regen BioPharma pink sheet.
Regen |
Regen BioPharma Company Current Liabilities Analysis
Regen BioPharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Regen BioPharma Current Liabilities | 649 K |
Most of Regen BioPharma's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regen BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Regen BioPharma has a Current Liabilities of 649 K. This is 99.96% lower than that of the Healthcare sector and 99.88% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Regen Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regen BioPharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regen BioPharma could also be used in its relative valuation, which is a method of valuing Regen BioPharma by comparing valuation metrics of similar companies.Regen BioPharma is currently under evaluation in current liabilities category among its peers.
Regen Fundamentals
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 22.4 M | |||
| Shares Outstanding | 5.05 B | |||
| Shares Owned By Insiders | 0.06 % | |||
| Price To Sales | 89.73 X | |||
| Revenue | 235.52 K | |||
| Gross Profit | 235.52 K | |||
| EBITDA | 2.44 M | |||
| Net Income | 2.44 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Beta | 3.36 | |||
| Market Capitalization | 10.1 M | |||
| Total Asset | 559 K | |||
| Retained Earnings | (17.78 M) | |||
| Working Capital | (478 K) | |||
| Current Asset | 171 K | |||
| Current Liabilities | 649 K | |||
| Z Score | -26.6 | |||
| Net Asset | 559 K |
About Regen BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regen BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regen BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regen BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Regen BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.